LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Publication | Closed Access

DOI

Citations

References

2023

Year

Yelena Y. Janjigian, S-E. Al-Batran, Zev A. Wainberg, Eric Van Cutsem, Daniela Molena, Kei Muro, Woo Jin Hyung, Lucjan Wyrwicz, D-Y. Oh, Takeshi Omori,

Annals of Oncology

Tumor BiologySurgical OncologyOncologyEsophageal CancerGastrointestinal OncologyMedicineResectable GastricPathologyCancer GenomicsInterim ResultsMolecular OncologyCancer TreatmentCancer GeneticsPharmacologyGastroesophageal Junction CancerCancer Research